Mar 19 2025 9 mins
Visit https://www.peervoice.com/QCE860 to view the entire programme with slides. After completing “Amrita Krishnan, MD - The Specifics of Bispecific Antibodies for Multiple Myeloma”, participants will be able to: Identify patients who may benefit from bispecific antibody therapy based on individual factors (such as disease characteristics or prior lines of treatment); and Implement evidence-based best practices in the recognition and management of adverse events associated with the use of bispecific antibodies in patients with multiple myeloma (MM).